Hemorheological Alterations in Patients with Heart Failure with Reduced Ejection Fraction Treated by Resveratrol

Hemorheological Alterations in Patients with Heart Failure with Reduced Ejection Fraction Treated by Resveratrol

Objectives. Several beneficial effects of resveratrol have already been published. This study evaluated the effect of resveratrol on the hemorheological parameters in patients with heart failure with reduced ejection fraction. Methods. In our double-blind, placebo-controlled human clinical trial, we...

Full description

Saved in:

Bibliographic Details
Main Authors:	Roland Gal, Dora Praksch, Peter Kenyeres, Miklos Rabai, Kalman Toth, Robert Halmosi, Tamas Habon
Format:	Article
Language:	English
Published:	Wiley 2020-01-01
Series:	Cardiovascular Therapeutics
Online Access:	http://dx.doi.org/10.1155/2020/7262474
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Heart failure with mildly reduced ejection fraction: retrospective study of ejection fraction trajectory risk
by: Robert J.H. Miller, et al.
Published: (2022-06-01)

Characteristics and Outcomes of Heart Failure Outpatients with Improvement in Ejection Fraction in Qatar
by: Rasha Kaddoura, et al.
Published: (2024-07-01)

Challenges in the diagnosis of heart failure with preserved ejection fraction in individuals with obesity
by: Bas M. van Dalen, et al.
Published: (2025-02-01)

PYTHON INTERFACE DESIGN FOR MICROPHOTOGRAPHY ANALYSIS:APPLICATION TO EVALUATE THE HEMORHEOLOGICAL ACTIVITY OF QUERCETIN
by: P.Buszniez, et al.
Published: (2024-12-01)

Efficacy of sacubitril/valsartan among patients with chronic heart failure with reduced ejection fraction
by: Madiha Butt, et al.
Published: (2024-09-01)

Clinical characteristics and outcomes in Asian patients with heart failure with mildly reduced ejection fraction
by: Julian Cheong Kiat Tay, et al.
Published: (2024-07-01)

Real‐world clinical diagnostics of heart failure patients with reduced or preserved ejection fraction
by: Jenni Huusko, et al.
Published: (2020-06-01)

Microvascular disease and heart failure with reduced and preserved ejection fraction in type 2 diabetes
by: Ify R. Mordi, et al.
Published: (2020-06-01)

Rehospitalization burden and morbidity risk in patients with heart failure with mid‐range ejection fraction
by: Enrique Santas, et al.
Published: (2020-06-01)

Impact of adjunctive tolvaptan on sympathetic activity in acute heart failure with preserved ejection fraction
by: Shunsuke Tamaki, et al.
Published: (2020-06-01)

Clinical characteristics and frailty status in heart failure with preserved vs. reduced ejection fraction
by: Tomoyuki Hamada, et al.
Published: (2022-06-01)

Prevalence and prognostic value of ventricular conduction delay in heart failure with preserved ejection fraction
by: Anouk Achten, et al.
Published: (2025-04-01)

Using Deep Learning to Identify High-Risk Patients with Heart Failure with Reduced Ejection Fraction
by: Zhibo Wang, et al.
Published: (2021-07-01)

Economic impact of heart failure with preserved ejection fraction: insights from the ALDO‐DHF trial
by: Djawid Hashemi, et al.
Published: (2020-06-01)

Sacubitril/valsartan in patients with heart failure with reduced ejection fraction with end‐stage of renal disease
by: Seonhwa Lee, et al.
Published: (2020-06-01)

Relation of left atrial overload indices with prognostic endpoints in heart failure and preserved ejection fraction
by: Shiro Hoshida, et al.
Published: (2022-06-01)

Upregulated FoxO1 promotes arrhythmogenesis in mice with heart failure and preserved ejection fraction
by: Thassio Mesquita, et al.
Published: (2025-01-01)

Association between insulin resistance indices and outcomes in patients with heart failure with preserved ejection fraction
by: Weicheng Ni, et al.
Published: (2025-01-01)

Safety and efficacy of catheter ablation in atrial fibrillation patients with heart failure with preserved ejection fraction
by: Songbing Long, et al.
Published: (2025-01-01)

Gender differences in the prognostic impact of uric acid in patients with heart failure and preserved ejection fraction
by: Xuefeng Wu, et al.
Published: (2025-01-01)

Caloric restriction and its mimetics in heart failure with preserved ejection fraction: mechanisms and therapeutic potential
by: Alexander Fuerlinger, et al.
Published: (2025-01-01)

Single-cell transcriptomic profiling of heart reveals ANGPTL4 linking fibroblasts and angiogenesis in heart failure with preserved ejection fraction
by: Guoxing Li, et al.
Published: (2025-02-01)

Efficacy of vericiguat in patients with chronic heart failure and reduced ejection fraction: a prospective observational study
by: Yinge Zhan, et al.
Published: (2025-02-01)

Electrocardiography-based artificial intelligence predicts the upcoming future of heart failure with mildly reduced ejection fraction
by: Dae-Young Kim, et al.
Published: (2025-02-01)

Early experience of Sacubitril–Valsartan in heart failure with reduced ejection fraction in real‐world clinical setting
by: Charlotte Nordberg Backelin, et al.
Published: (2020-06-01)

Variation in clinical and patient‐reported outcomes among complex heart failure with preserved ejection fraction phenotypes
by: Kelsey M. Flint, et al.
Published: (2020-06-01)

Impact of Initial Heart Rate, Diastolic Pressure, and Pulse Pressure on Prognostic Outcomes in Heart Failure Patients with Mildly Reduced Ejection Fraction
by: Hu H, et al.
Published: (2025-01-01)

Impact of geriatric nutritional risk index and diabetes mellitus on prognosis in ischaemic heart failure with reduced ejection fraction
by: Zhiyong Shi, et al.
Published: (2025-02-01)

AdipoRon ameliorates the progression of heart failure with preserved ejection fraction via mitigating lipid accumulation and fibrosis
by: Wuping Tan, et al.
Published: (2025-02-01)

Failure and Ejection Behavior of Concrete Materials under Internal Blast
by: Haifu Wang, et al.
Published: (2016-01-01)

Phenotypic Trajectories From Acute to Stable Phase in Heart Failure With Preserved Ejection Fraction: Insights From the PURSUIT‐HFpEF Study
by: Yuki Matsuoka, et al.
Published: (2025-02-01)

Development and Validation of a Nomogram Model for Predicting the Risk of Readmission in Patients with Heart Failure with Reduced Ejection Fraction within 1 Year
by: Yue Hu, et al.
Published: (2022-01-01)

Current Treatment of Heart Failure with Preserved Ejection Fraction: Should We Add Life to the Remaining Years or Add Years to the Remaining Life?
by: Jia Li, et al.
Published: (2013-01-01)

Effects of Fasudil on Patients with Pulmonary Hypertension Associated with Left Ventricular Heart Failure with Preserved Ejection Fraction: A Prospective Intervention Study
by: Xiang Zhang, et al.
Published: (2018-01-01)

Left Ventricular End-Systolic Volume Is a Reliable Predictor of New-Onset Heart Failure with Preserved Left Ventricular Ejection Fraction
by: Marina Kato, et al.
Published: (2020-01-01)

Sacubitril/valsartan on right ventricular-pulmonary artery coupling and albumin-bilirubin score in heart failure in Chinese patients with reduced ejection fraction
by: Yanan Shi, et al.
Published: (2025-01-01)

Yiqi Fumai Lyophilized injection protects cardiac contractility in a rat model of heart failure with reduced ejection fraction by modulating SERCA2
by: Yongwei Nie, et al.
Published: (2025-02-01)

Association between prognosis and the use of angiotensin‐converting enzyme inhibitors and/or angiotensin II receptor blockers in frail patients with heart failure with preserved ejection fraction
by: Akihiro Sunaga, et al.
Published: (2022-06-01)

Predictors of Unfavorable Outcomes in Patients with Atrial Fibrillation and Concomitant Heart Failure with Different Ejection Fractions: RIF-CHF Register One-Year Follow-Up
by: Igor Zhirov, et al.
Published: (2019-01-01)

Comparison of carvedilol vs. bisoprolol for heart failure with reduced ejection fraction (HFrEF): A systematic review and meta-analysis from the Asian population
by: Yedy Purwandi Sukmawan, et al.
Published: (2025-01-01)